RTP Mobile Logo
What Oncology Nurses Need to Know: Role of Hormonal Therapy in the Management of Prostate Cancer (Webinar Video Proceedings)
Released November 2020

Proceedings from an oncology nursing educational webinar held in partnership with the ONS Bridge virtual conference. Featuring perspectives from Dr Andrew J Armstrong, Ms Molly Kim, Ms Ellen Leidig and Dr William K Oh. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with prostate cancer.

    LEARNING OBJECTIVES

    • Assess the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
    • Counsel patients with metastatic hormone-sensitive prostate cancer (mHSPC) about cytotoxic and secondary hormonal therapy to ensure appropriate and informed shared decision-making.
    • Recall the recent FDA approvals of enzalutamide and apalutamide for patients with mHSPC, and appreciate how these agents can be integrated into clinical practice.
    • Recognize how prior therapeutic exposure and patient and disease characteristics factor into the selection and sequencing of available systemic treatments for metastatic CRPC.
    • Educate patients about the side effects associated with approved therapies commonly employed in the management of advanced prostate cancer, and provide preventive strategies to reduce or ameliorate these toxicities.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENTS
    Audio Program: This educational activity for 1.75 contact hours is provided by RTP during the period of November 2020 through November 2021.

    This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1.25 contact hours is provided by RTP during the period of November 2020 through November 2021.

    This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSBridge20/Prostate/ILNA .

    ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSBridge20/Prostate/CNE. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSBridge20/Prostate/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSBridge20/Prostate/Video/CNE. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSBridge20/Prostate.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Andrew J Armstrong, MD, ScM
    Professor of Medicine, Surgery, Pharmacology and Cancer Biology
    Director of Research
    Duke Cancer Institute Center for Prostate and Urologic Cancers
    Divisions of Medical Oncology and Urology
    Duke University
    Durham, North Carolina

    Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc, Janssen Biotech Inc, Merck, Pfizer Inc, Tolero Pharmaceuticals; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc.

    Molly Kim, MSN, NP-C
    Nurse Practitioner
    Genitourinary Medical Oncology
    Mount Sinai Hospital
    New York, New York

    No financial interests or affiliations to disclose.

    Ellen Leidig, MSN, FNP-BC, RN
    Nurse Practitioner, GU Medical Oncology
    Duke Cancer Center
    Durham, North Carolina

    No financial interests or affiliations to disclose.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Icahn School of Medicine at Mount Sinai
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    Mount Sinai Health System
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CPS Companion Diagnostics, Janssen Biotech Inc, Sanofi Genzyme, Sema4, TeneoBio.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Pfizer Inc.

    Release date: November 2020
    Expiration date: November 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):